Home Home Our Science+Pipeline News About Foreign cooperation Join Us

Shize's Development History

XellSmart is committed to providing large-scale, low-cost stem cell therapy solutions for a series of major diseases such as Parkinson's disease for which there is no clinical solution.

Under the leadership of Dr. Li Xiang, XellSmart has independently designed and constructed a 1,600 m2 R&D center and is building a 3,500 m2 production transformation base. Xellsmart has established key technology platforms, such as the reprogramming of iPS cell lines, the iPSC gene editing platform, and the transfer of iPSCs to different sub-type neuronal cells, animal model of Parkinson's disease for evaluation of the safety and efficacy of cell-based drugs, and issued relevant patents.

At present, XellSmart has completed successive rounds financing with total amount over 100 million RMB. The investors includes FreesFund (leading the angel round), Lilly Asia Ventures, Qiming Ventures (co-leading the PreA round), Sequoia China (leading the PreA+ round), YuanBio Venture Capital, TEDA Venture Capital, Tao Capital, NEXT Capital, and Leader Venture Capital.

Team Awards

Striving Continuously to Strengthen Oneself Have Ample Virtue and Carry All Things


Patent Down to earth, Look up at the starry sky


In 2021, Dr. Li Xiang took the lead in founding XellSmart, serving as the CEO and CSO. It united Dr. Xiao, Dr. Yan, Manager Qiu and brought together Dr. Chen, Dr. Huang, Dr. Zhu, and VP Yao, a group of experts from science and industry. At present, there are nearly 60 full-time employees, 10 Ph.D./post-doctoral fellows, and more than 65% of the postgraduates with master's degree or above.
  • Li Xiang (Alias: Xiang Ye)

    Founder, Chairman, CEO and CSO of Shize Biopharmaceutical Co., Ltd

    Ph.D. in Life Sciences, Peking University

    Postdoc at the University of Wisconsin-Madison

    Vice Chairman of the Eighth Council of Jiangsu Biotechnology Association

    Senior Engineer of Biomedical Engineering, Suzhou City, Jiangsu Province

    Suzhou Industrial Park Technology Leading Talent

    2021 Golden Award 30 Outstanding Young Innovators in China

    Former Senior Scientist of Sana Biotechnology (NASDAQ: SANA)

Angel round investment team

Top investment team working side by side with XellSmart Bio
  • FreesFund

    FREES We firmly believe that being
    right is more important than being


  • Qiming Venture Partners

    Enlighten the public with wisdom
    and learn with diligence。

    Qiming Venture Partners

  • Lilly Asia Ventures

    We fight disease, save lives and
    improve human health Provide
    industry experience, global
    resources and long-term capital.

    Lilly Asia Ventures

  • Sequoia China

    Sequoia China, the entrepreneur
    behind the entrepreneur, is
    committed to discovering and
    cultivating [towering trees] in the

    Sequoia China

  • TEDA Venture Capital

    TEDA Tech We believe that
    technology creates value.

    TEDA Venture Capital

  • YuanBio Venture Capital

    professional focus, steady and

    YuanBio Venture Capital

  • NEXT Capital

    Innovator's first money
    Discover the Next Big Thing.

    NEXT Capital

  • Tao Capital

    Focus on medical and health
    investment to promote the
    development of life sciences.

    Tao Capital


Patients first, "Blade" second, shareholders third

Development History

In January 2022

In January 2022, XellSmart completed a Pre-A+ round of financing of nearly 100 million RMB.

In January 2022

In January 2022, XellSmart won the 2021 bioBAY "Growth Award".

In December 2021

In December 2021, XellSmart won the winning project of the National Disruptive Technology Innovation Competition.

In December 2021

In December 2021, XellSmart won the Golden Award and the Most Growing Innovative Company in 2021.

In December 2021

In December 2021, Dr. Li Xiang, founder and chairman of XellSmart, was awarded the Golden Award · 2021 China's 30 Outstanding Young Innovators

In October 2021

In October 2021, XellSmart was awarded the 2021 Top 50 Most Innovative Chinese Biopharmaceutical Enterprises.

In September 2021

In September 2021, XellSmart won the first prize in the final of the first Sino-Russian Youth Innovation, Entrepreneurship and Creativity Competition in the pharmaceutical and health industry.

In September 2021

In September 2021, XellSmart biology completed nearly 100 million yuan of pre-A round of financing.

In July 2021

In July 2021, XellSmart was elected as the executive vice-chairman unit of Jiangsu Biotechnology Association.

In June 2021

In June 2021, XellSmart won the excellent project (the highest award) of the Zhangjiang Cell Industry International Summit Roadshow.

In June 2021

In June 2021, XellSmart officially entered the Shanghai Jinling Valley Base.

In June 2021

In June 2021, XellSmart Bio has completed tens of millions of angel round investment.

In May 2021

In May 2021, XellSmart Bio officially announced the establishment.

Team Background